Abstract
In The Lancet, Else Sandset and colleagues1 report the results of the Scandinavian Candesartan Acute Stroke Trial (SCAST), in which they aimed to find out whether careful lowering of blood pressure, with the angiotensin-receptor blocker candesartan, would be beneficial in patients with acute ischaemic and haemorrhagic stroke.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
